Why biotech needs fewer intermediaries and more owners

Biotechnology is one of the most complex industries in the modern economy. It sits at the intersection of science, medicine, regulation, manufacturing and capital. Because of this complexity, emerging biotech ecosystems often attract a wide range of advisers, consultants, intermediaries and facilitators who promise to accelerate growth.

Yet the most successful biotech ecosystems are rarely built by intermediaries.

They are built by owners.

In the context of biotechnology, ownership does not simply mean equity. It means responsibility for outcomes. It means individuals and institutions willing to make decisions, commit capital, build infrastructure, hire talent and accept the risk that accompanies long development cycles.

Intermediaries play a role in early-stage ecosystem development. Consultants can provide expertise, advisers can offer guidance and external partners can help transfer knowledge. But when intermediaries dominate decision-making, execution slows. Strategies become theoretical exercises rather than operational road maps.

Biotech requires builders, not just advisers.

This distinction becomes particularly important in emerging biotech markets. Many countries entering the biotechnology sector understandably seek external expertise from established global hubs. These partnerships can accelerate learning and introduce best practices.

However, ecosystems cannot outsource ownership.

Local fund managers, operators, regulators and entrepreneurs must eventually take responsibility for building companies, managing capital and making investment decisions. Without this ownership culture, ecosystems remain dependent on external validation rather than internal capability.

In biotechnology, execution is everything. Scientific discovery alone does not create industry. Translating research into therapies requires years of clinical development, regulatory engagement, manufacturing scale-up and commercial strategy. Each stage demands disciplined decision-making and long-term commitment.

This is why ecosystems driven primarily by advisory frameworks often struggle to move from ambition to implementation.

Owners build infrastructure.

They establish laboratories, manufacturing facilities, clinical networks and regulatory pathways. They hire scientists, engineers and operational leaders. They invest in talent development and accept the financial burden that accompanies early-stage industrial development.

Most importantly, owners stay when challenges appear.

Biotech development rarely follows a predictable timeline. Clinical trials can fail, regulatory approvals can take longer than expected and scientific breakthroughs can take years to materialize. Ecosystems built on advisory enthusiasm often retreat when progress slows.

Ownership culture does the opposite.

It recognizes that setbacks are part of the process and adjusts strategy accordingly. Instead of abandoning projects, owners refine them. Instead of withdrawing capital, they redeploy it more intelligently.

Saudi Arabia’s biotechnology ambitions make this distinction particularly relevant.

The Kingdom has made significant investments in research, infrastructure and life sciences strategy. These investments create a strong foundation, but the next phase will depend on operational ownership rather than strategic planning alone.

Local investors must move beyond observing global biotech markets to actively taking part in them. Fund managers must develop the confidence to lead deals rather than merely co-investing behind international funds. Entrepreneurs must build companies designed to operate globally while rooted locally.

Ownership also requires alignment between capital and execution.

Investors who deploy capital into biotechnology must understand the timelines involved. Unlike software startups, biotech companies cannot compress scientific validation into short funding cycles. Drug development, diagnostics, and advanced therapeutics require patience and technical expertise.

When capital is aligned with ownership, ecosystems gain stability.

Investors support companies through multiple stages of development. Founders focus on scientific and operational progress rather than constant fundraising. Institutions provide regulatory clarity and infrastructure support.

This alignment transforms biotechnology from an experimental sector into a functioning industry.

Global biotech hubs illustrate this principle clearly. In regions such as Boston, San Diego and parts of Europe, the ecosystems are driven by a dense network of founders, scientists, venture investors, and experienced operators who repeatedly build and scale companies.

These individuals are not intermediaries observing the market.

They are owners shaping it.

For emerging biotech ecosystems, the lesson is straightforward. Expertise is valuable, but execution requires accountability. Advice can guide strategy, but only ownership can deliver outcomes.

Biotechnology will ultimately be built by those willing to carry responsibility through uncertainty.

In that sense, the future of biotech belongs not to those who facilitate conversations about innovation, but to those who take ownership of building it.

• Dr. Huda Alfardus is a businesswoman and biotech investment expert focused on innovation, venture capital, and expanding women’s participation in business and investment markets.